Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pharmacia & Upjohn epirubicin

Executive Summary

FDA's Oncologic Drugs Advisory Committee will meet on the afternoon of June 7 to discuss epirubicin as a component of adjuvant therapy in patients with evidence of axillary node tumor involvement following resection of stage II or stage III breast cancer. The morning session will convene at 10:30 a.m. to discuss use of time to progression as a primary endpoint in Phase III breast cancer trials
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS034101

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel